Business Wire

European Medicines Agency Validates Pierre Fabre’s Application for Combination of BRAFTOVI® (encorafenib), MEKTOVI® (binimetinib) and cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer

Share

Pierre Fabre today announced that the European Medicines Agency (EMA) has validated for review the filing of Type II variation applications for BRAFTOVI ® (encorafenib) + MEKTOVI ® (binimetinib) in combination with cetuximab for the treatment of patients with BRAFV600E -mutant metastatic colorectal cancer (mCRC). Validation of the applications confirms the submission is complete, and the EMA will now begin its review procedure.

BRAF-mutant mCRC is a devastating cancer, for which there are currently limited treatment options that can prolong the lives of patients. The acceptance of our application by the EMA brings us one step closer to realising our commitment towards advancing care for patients living with difficult-to-treat cancers,” said Jean-Luc Lowinski, CEO of the Pierre Fabre Pharmaceuticals Division. “If approved, BRAFTOVI+MEKTOVI in combination with cetuximab has the potential to be the first chemotherapy-free, targeted regimen for patients with BRAFV600E -mutant mCRC.”

The application is based on data from the pivotal Phase 3 BEACON CRC trial. The randomised, open-label, global study evaluates the efficacy and safety of BRAFTOVI+MEKTOVI in combination with cetuximab in patients with advanced BRAFV600E -mutant mCRC whose disease has progressed after one or two prior lines of therapy. This is a first-of-its-kind study, as the trial is designed to test combined BRAF/MEK targeted therapies in individuals with BRAF-mutant mCRC.1 Expanded interim results from this trial were previously presented during a late-breaking oral session at the 2019 European Society for Medical Oncology (ESMO) Congress and simultaneously published online in the New England Journal of Medicine in September 2019.

The results of the BEACON CRC trial showed significant improvements in overall survival (OS) and objective response rates (ORR) for BRAFTOVI+MEKTOVI in combination with cetuximab and BRAFTOVI in combination with cetuximab, compared with cetuximab plus irinotecan-containing regimens. Both combination regimens demonstrated a safety profile with no unexpected toxicities.2

Patients with BRAF-mutant CRC generally have a poor prognosis with current available treatments. Currently, there are no approved therapies in Europe specifically indicated for this high medical need population.3–10 BRAF mutations are estimated to occur in approximately 8-12% of patients with mCRC, and V600E is the most common mutation.11–19

About Colorectal Cancer
Worldwide, colorectal cancer is the third most common type of cancer in men and the second most common in women, with approximately 1.8 million new diagnoses in 2018. Globally in 2018, approximately 881,000 deaths were attributed to colorectal cancer.20 Every year more than 450,000 people in Europe are diagnosed with colorectal cancer and approximately 230,000 will die of their disease.21 BRAF mutations are estimated to occur in approximately 8-12% of patients with mCRC and represent a poor prognosis for these patients.11-18,22 The V600E mutation is the most common BRAF mutation and the risk of mortality in CRC patients with the BRAFV600E mutation is more than two times higher than for those with wild-type BRAF.19,21,23

About BEACON CRC
BEACON CRC is a randomised, open-label, global trial evaluating the efficacy and safety of BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in combination with cetuximab in patients with BRAFV600E -mutant mCRC whose disease has progressed after one or two prior regimens. BEACON CRC is the first and only Phase 3 trial designed to test a BRAF/MEK combination targeted therapy in BRAFV600E -mutant mCRC. Thirty patients were treated in the safety lead-in and received BRAFTOVI+MEKTOVI in combination with cetuximab (BRAFTOVI 300 mg daily, MEKTOVI 45 mg twice daily and cetuximab per label). Of the 30 patients, 29 had a BRAFV600 mutation. Microsatellite instability high, resulting from defective DNA mismatch repair, was detected in only one patient. As previously announced, BRAFTOVI+MEKTOVI in combination with cetuximab showed an acceptable safety profile that supported initiation of the randomised portion of the trial. The randomised portion of the BEACON CRC trial is designed to assess the efficacy of BRAFTOVI in combination with cetuximab with or without MEKTOVI compared with cetuximab and irinotecan-based therapy. 665 patients were randomised 1:1:1 to receive BRAFTOVI+MEKTOVI in combination with cetuximab, BRAFTOVI in combination with cetuximab or the control arm (irinotecan-based therapy and cetuximab). The study was amended to include an interim analysis of endpoints, including ORR. The primary OS endpoint is a comparison of BRAFTOVI+MEKTOVI in combination with cetuximab with the control arm. Secondary endpoints address efficacy of BRAFTOVI in combination with cetuximab compared with the control arm and compared with BRAFTOVI+MEKTOVI in combination with cetuximab. Other secondary endpoints include progression-free survival, duration of response, safety and tolerability. Health-related quality of life data will also be assessed. The trial is being conducted at over 200 investigational sites in North America, South America, Europe and the Asia-Pacific region. The BEACON CRC trial is being conducted with support from Pierre Fabre, Ono Pharmaceutical Co. Ltd., and Merck KGaA, Darmstadt, Germany (support is for sites outside of North America).

About BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib)
BRAFTOVI® (encorafenib) is an oral small-molecule BRAF kinase inhibitor and MEKTOVI® (binimetinib) is an oral small-molecule MEK inhibitor that target key enzymes in the MAPK signalling pathway (RAS-RAF-MEK-ERK). Inappropriate activation of proteins in this pathway has been shown to occur in many cancers, including melanoma, colorectal cancer, non-small cell lung cancer and others. The combination of BRAFTOVI+MEKTOVI is currently only approved for use in unresectable or metastatic melanoma with a BRAFV600 mutation. The use of BRAFTOVI+MEKTOVI in combination with cetuximab for the treatment of patients with BRAFV600E -mutant mCRC is investigational and not approved by the European Commission (EC).

On 20 September 2018, the EC granted marketing authorisation for the combination of BRAFTOVI and MEKTOVI for the treatment of adult patients with unresectable or metastatic melanoma with a BRAFV600 mutation, as confirmed by a validated test.24,25 The EC decision is applicable to all 28 European Union member states plus Iceland, Liechtenstein and Norway. BRAFTOVI and MEKTOVI have also received regulatory approval in the United States (U.S.), Australia and Japan. On 27 June 2018, the combination of BRAFTOVI and MEKTOVI was approved by the FDA for the treatment of unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation, as detected by an FDA-approved test.26,27 BRAFTOVI and MEKTOVI are not indicated for treatment of patients with wild-type BRAF melanoma. In Japan, the combination is approved for unresectable melanoma with a BRAF mutation. BRAFTOVI and MEKTOVI have received regulatory approvals in Australia and Switzerland for BRAFTOVI and MEKTOVI for the treatment of unresectable melanoma with a BRAF mutation submitted by Pierre Fabre.

Pfizer has exclusive rights to BRAFTOVI® and MEKTOVI® in the U.S. and Canada. Pfizer has granted Ono Pharmaceutical Co. Ltd. exclusive rights to commercialise both products in Japan and South Korea, Medison exclusive rights to commercialise both products in Israel and Pierre Fabre exclusive rights to commercialise both products in all other countries, including Europe, Latin America and Asia (excluding Japan and South Korea).

About Pierre Fabre
With a portfolio representing a continuum of activities spanning from prescription drugs and consumer healthcare products to dermo-cosmetics, Pierre Fabre is the 2nd largest dermo-cosmetics laboratory in the world, the 2nd largest private French pharmaceutical group and the market leader in France for products sold over the counter in pharmacies. Its portfolio includes several global brands and franchises among which Eau Thermale Avène, Klorane, Ducray, René Furterer, A-Derma, Galénic, Elancyl, Naturactive, Pierre Fabre Health Care, Pierre Fabre Oral Care, Pierre Fabre Dermatologie and Pierre Fabre Oncologie.

In 2018, Pierre Fabre generated 2.3 billion euros in revenues, of which 64% came from its international business and 61% from its dermo-cosmetics division. Pierre Fabre, which has always been headquartered in the South-West of France, counts about 11,000 employees worldwide, owns subsidiaries and offices in over 40 countries and enjoys distribution agreements in over 130 countries. In 2018, Pierre Fabre dedicated 187 million euros to R&D efforts, split between oncology, dermatology, consumer healthcare and dermo-cosmetics.

Pierre Fabre is 86%-owned by the Pierre Fabre Foundation, a government-recognised public-interest foundation, and secondarily by its own employees through an international employee stock ownership plan.

In 2019, Ecocert Environment assessed the Group’s corporate social and environmental responsibility approach according to the ISO 26000 standard on sustainable development and awarded it the ECOCERT 26000 “Excellence” level.

www.pierre-fabre.com
@PierreFabre

References
[1] ASCO Post. BEACON CRC: Encorafenib/Binimetinib/Cetuximab Improves Survival in BRAF V600E–Mutated Metastatic Colorectal Cancer. Available at: https://ascopost.com/issues/august-10-2019/beacon-crc/. Accessed November 2019.
[2] Tabernero J, et al. ESMO 2019 (Abstract No. LBA32).
[3] Saridaki Z, et al. PLoS One. 2013;8(12):e84604.
[4] Loupakis F, et al. Br J Cancer. 2009;101(4):715–21.
[5] Corcoran RB, et al. Cancer Discov. 2012;2(3):227–35.
[6] Kopetz S, et al. J Clin Oncol. 2017;35(15 suppl):3505.
[7] De Roock W, et al. Lancet Oncol. 2010;11(8):753–62.
[8] Ulivi P, et al. J Transl Med. 2012;10:87.
[9] Peeters M, et al. J Clin Oncol. 2014;32(15 suppl):3568.
[10] Ardekani R, et al. PLoS One. 2012;7(7):e40506.
[11] Maughan TS, et al. Lancet. 2011;377:2103–14.
[12] Souglakos J, et al. Br J Cancer. 2009;101:465–72.
[13] Richman SD, et al. J Clin Oncol. 2009;27:5931–7.
[14] Tran B, et al. Cancer. 2011;117:4623–32.
[15] Yokota T, et al. Br J Cancer. 2011;104:856–62.
[16] Tie J, et al. Int J Cancer. 2011;128:2075–84.
[17] Loupakis F, et al. Br J Cancer. 2009;101:715.
[18] Tviet KM, et al. J Clin Oncol. 2012;30:1755–62.
[19] Sclafani F, et al. Crit Rev Oncol Hematol. 2013;87:55–68.
[20] The Global Cancer Observatory, 2018. International Agency for Research on Cancer, World Health Organization. Available at: https://gco.iarc.fr/today/online-analysis-multi-bars. Accessed November 2019.
[21] Colorectal Cancer in Europe: A Framework for Improving Outcomes for Patients. EuropaColon. Available at: https://webgate.ec.europa.eu/chafea_pdb/assets/files/pdb/20124301/20124301_d04-00_en_ps_ecwhitepaper.pdf. Accessed November 2019.
[22] Vecchione L, et al. Cell. 2016;165(2):317–30.
[23] Safaee Ardekani G, et al. PLoS One. 2012;7(10):e47054.
[24] European Medicines Agency. BRAFTOVI® (encorafenib) Summary of Product Characteristics. Available at: https://www.ema.europa.eu/documents/product-information/braftovi-epar-product-information_en.pdf. Accessed November 2019.
[25] European Medicines Agency. MEKTOVI® (binimetinib) Summary of Product Characteristics. Available at: https://www.ema.europa.eu/documents/product-information/mektovi-epar-product-information_en.pdf. Accessed November 2019.
[26] Array BioPharma. BRAFTOVI® (encorafenib) US Prescribing Information 2018. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210496lbl.pdf. Accessed November 2019.
[27] Array BioPharma. MEKTOVI® (binimetinib) US Prescribing Information 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210498s001lbl.pdf. Accessed November 2019.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Pierre Fabre
Valérie Roucoules
(33) 1 49 10 83 84
valerie.roucoules@pierre-fabre.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Experian Announces New Commitment to a Flexible Working Culture11.5.2021 19:26:00 EEST | Press release

Experian, the global information services company, has today announced a new global approach to work. The aim is to take the learnings from the experience of Covid-19 lockdown and create a working environment which suits everyone’s situation. Experian is committing to promote more individual choice by creating a new hybrid model, where employees will be encouraged to ‘work your way’. Through the lockdown, Experian moved its global operations to remote working with very limited disruption. Most employees will be offered increased flexibility, with the majority moving to a hybrid model, some working fully remotely, and some in the office. Experian – which operates in 45 countries around the world – believes this will continue to boost productivity and improve the work / life balance options for its 17,800 global employee base. What the Covid-19 crisis has reminded us, beyond everything else, is that we are all individuals living very different lives. That’s prompted Experian to go down t

SentinelOne is the Only Vendor to Score Highest Across All Three Gartner Critical Capabilities Use Cases11.5.2021 18:40:00 EEST | Press release

SentinelOne, the autonomous cybersecurity platform company, today announced that Gartner has positioned SentinelOne with the highest scores in all three use cases; Type A, B, & C in Gartner’s 2021 Critical Capabilities for Endpoint Protection Platforms report1. Out of the 19 vendors included in the report, SentinelOne is the only vendor that received the highest score across all three Critical Capabilities use cases: Customer use case Type A is focused on “lean forward” organizations that adopt new technologies very early in the adoption cycle. Customer use case Type B is focused on “overall value” by weighing the risks of the early use of new technology against the benefits. Customer use case Type C represents organizations that typically view technology as an expense or operational necessity and use it as a means to reduce costs. “We believe receiving the highest product score across all three customer use cases in the 2021 Critical Capabilities for Endpoint Protection Platforms vali

1E Challenges DEM Market to Deliver More, Launching New Unified eXperience Management Category11.5.2021 17:35:00 EEST | Press release

1E , innovators in endpoint management, today announced Unified eXperience Management (UXM) , a new category that seeks to address the siloed approach inherent in tools in the Digital Experience Monitoring (DEM) space. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210511005842/en/ 1E Tachyon Platform: Unified eXperience Management to improve the Digital Experience of all employees (Graphic: Business Wire) Due to the relative immaturity of the Digital Experience Management category, most tooling is focused on identifying and reporting on the scale of the problem, scoring, and issue identification. These tools create analytics silos that give insight, but are uncoupled from the automation technology that can actually improve end-user experience at an enterprise scale. Meanwhile, employees are becoming increasingly more frustrated, with 56% feeling dissatisfied with their IT experience. Organizations looking to improve the dig

Biorasi Receives ISO 9001:2015 Certification for Quality Management11.5.2021 17:30:00 EEST | Press release

Biorasi, a leading global full-service contract research organization (CRO), is proud to announce the achievement of ISO 9001:2015 certification. By earning this ISO accreditation, Biorasi has demonstrated dedication to the practice of quality assurance within the clinical trials industry and commitment to quality excellence for individual clinical studies. “ISO 9001:2015 certification is a big deal for Biorasi,” said Chris O’Brien, CEO at Biorasi. “It is a powerful, independent validation of the quality of our processes. It sends a message to potential sponsors across the globe that Biorasi cares deeply about quality. It tells them they can trust us.” Biorasi was presented with their ISO 9001:2015 certification on May 5, 2021, joining the ranks of other quality-focused organizations, including our preferred vendor, IBM Watson Health. “Our Quality Policy is driven by the fundamental understanding that patients and their families are affected by the decisions we make,” said Todd Brill,

Alvotech Seeks to End AbbVie’s Wrongful Monopoly on Humira and Bring Affordable Arthritis Treatment to U.S.11.5.2021 17:23:00 EEST | Press release

Alvotech today filed a federal lawsuit (Case 1:21-cv-00589) seeking to end the monopoly that pharmaceutical giant AbbVie has long-maintained on the adalimumab market, sold as Humira. Humira is the highest grossing prescription drug in the United States with over $16 billion in sales in 2020 (nearly $20Bn globally). Alvotech has developed a biosimilar (analogous to a generic) of Humira called AVT02, the first-filed biosimilar drug equal in strength to Humira’s latest formulation, which AbbVie markets as a high-concentration, pain-free drug. The company is also developing AVT02 as an interchangeable product and it expects results from its ongoing interchangeability study in Q2 of this year. AVT02 could save U.S. taxpayers and the overall healthcare system $8-10 billion annually. “Our new product will be a gamechanger that will provide consumers who are suffering from chronic pain with significant savings, and we look forward to bringing this drug onto the market as soon as possible,” sai

The United Kingdom: Biolog-id and Nicholson Consulting Ltd Cooperate to Develop a Demonstration Lab to Showcase Biolog Transfusion Solution11.5.2021 16:01:00 EEST | Press release

Biolog-id, a global service provider of connected healthcare solutions, and Nicholson Consulting Ltd, an innovative consulting and engineering company specialized in the blood transfusion field, join their forces to set up a demonstration lab located at Malvern Hills Science Park, in the south of Birmingham. This co-branded demo environment will showcase to the UK market the biolog-id’s cutting-edge product-line: Biolog Transfusion Solution. Based on the RFID technology, Biolog Transfusion Solution has been designed to respond to the needs of all the actors involved along the blood transfusion supply chain. By combining software, equipment and tags, this breakthrough innovation offers to manage in real-time each application area, from collection and manufacturing at the blood centre, central and remote inventory at the blood banks to blood compound administration at patient’s bedside. Flexible and reliable, the biolog-id technology generates value throughout the lifecycle of blood prod

Kong Konnect Now Generally Available With Multi-Geo Support: Offers End Users Breakthrough API and Microservices Connectivity11.5.2021 16:00:00 EEST | Press release

Kong Inc., the cloud connectivity company, today announced the general availability release of Kong Konnect, a service connectivity platform that enables the modern connected business. First previewed at Kong Summit 2020 in private beta, Kong Konnect provides end users with instant access to a comprehensive suite of tools that enable reliable, secure and observable connectivity across their APIs and microservices. The GA release features new multi-geo support, allowing users to physically locate services close to their businesses for privacy and regulatory compliance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210511005311/en/ The fully modular platform enables developers, architects and operators to accelerate application development cycles and provide connectivity between services for stellar digital experiences. Architects decouple connectivity concerns from microservices so that developers can focus on building appli

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom